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Background: Donor cell engraftment is critical for the success of allogeneic bone marrow transplants. Graft failure is a
result of donor cells either failing to engraft initially or being eliminated at later time points. Donor cell engraftment is
facilitated by donor T cells, which eliminate residual host hemato-lymphoid effector cells such as NK cells and T cells.
Methods: We aimed to explore the role of host hematopoietic cell derived IL-12 on donor cell engraftment in a
murine model of BMT. We established radiation chimeras by transplanting C57BL6/J (B6) mice with BM from either
congenic B6 mice or IL-12p40 KO mice. These WT→ WT or IL-12 KO→ WT chimeras then underwent a secondary
transplant with allogeneic (FVB) BM. Survival, engraftment, donor T cell expansion, cytokine production by donor T cells,
as well as expression of stimulatory markers on donor T cells was analyzed.
Results: Mice whose residual host hematopoietic cells were capable of producing IL-12 had modestly higher survival,
higher donor T cell engraftment, and significantly higher donor erythroid engraftment. We have also found that an
increased number of donor T cells in IL-12 KO→ WT chimeras have a regulatory phenotype, expressing FoxP3, producing
lower levels of TNF-α, higher levels of IL-10, and expressing higher levels of ICOS as well as PD-1 on CD4+ T cells.
Conclusions: To our knowledge, this is the first report of a beneficial role of IL-12 production by host cells in the context
of bone marrow engraftment in a murine model of BMT. These findings support the clinical use of exogenous IL-12 for
use in settings where graft failure is of concern.
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Donor hematopoietic cell engraftment is the cornerstone
of all successful allogeneic bone marrow transplantation
(BMT). Allograft rejection occurs when donor cells fail
to engraft initially, or when there is a loss of donor cells
at a later time point following initial engraftment. While
the overall frequency of graft failure in BMT is less than
5%, graft failure is still a major concern when the source
of the allograft is a T cell depleted (TCD) human
leukocyte antigen (HLA) – haploidentical donor, in cord
blood transplants [1], in BM grafts from unrelated* Correspondence: ewaller@emory.edu
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unless otherwise stated.donors [2], or in patients where non-myeloablative con-
ditioning is used. LeBlanc et al. examined patients with
various hematological malignancies or solid tumors that
had received non-myeloablative conditioning or a higher-
intensity conditioning regimen followed by a hematopoietic
stem cell transplant (HSCT) from either HLA-identical
siblings or unrelated donors [3]. It was found that 6/24
patients receiving non-myeloablative conditioning ex-
perienced graft failure, compared with 1/34 patients in
the higher intensity conditioned group [3].
The addition of donor T cells to the BM graft has been
shown to facilitate engraftment in animal models [4,5].
The current model for hematopoietic cell engraftment in
allogeneic BMT is that host dendritic cells (DC) activate
donor T cells, which then promote engraftment by elimin-
ating radio-resistant cytotoxic host immune cells, especiallytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been shown to initiate graft-versus-host disease (GvHD),
and inactivation of host DC can prevent GvHD [6]. The
interplay between residual host DC and T cells represents a
delicate balance between engraftment and GvHD.
We have recently shown that tumor-bearing mice receiv-
ing BM grafts which were depleted of myeloid DC (mDC)
had enhanced survival and donor T-cell expansion com-
pared with mice receiving unmanipulated BM grafts, which
contained both mDC and plasmacytoid DC (pDC) [7].
Using interleukin-12 knockout (IL-12p40 KO) mice as BM
donors, it was found that the increased survival in mice re-
ceiving mDC depleted grafts was dependent on the pro-
duction of IL-12p40 by donor pDC [7]. IL-12 is produced
by DCs that can drive the development of donor type 1
helper T-cells (TH1) and type 1 cytotoxic T-cells (Tc1). It
has also been shown that administration of exogenous
IL-12 in a mouse model of BMT can reduce GvHD while
preserving the graft-versus-leukemia effect (GvL) [8].
While the role of IL-12 has been extensively studied in
the context of GvL and GvHD, the role of IL-12 in graft
failure has yet to be fully examined. Administration of
exogenous IL-12 can protect the bone marrow from the
effects of lethal irradiation, at the expense of sensitizing
the intestinal tract [9]. Administration of exogenous IL-
12 at certain doses has also been shown to facilitate
hematopoietic engraftment following lethal irradiation
[10]. We aimed to explore the role of IL-12 produced by
residual host hematopoietic cells in donor cell engraft-
ment. As IL-12 can be produced by non-hematopoietic
cells, including keratinocytes, osteoblasts, epithelial cells,
and endothelial cells, we established radiation chimeras
in C57BL6/J (B6) mice in which only hematopoietic cells
lacked the ability to produce IL-12p40 [11,12]. After
confirmation of donor hematopoietic chimerism, mice
received lethal irradiation followed by an allogeneic
BMT (FVB or B10.BR→ B6 model). Survival, engraftment,
donor T cell expansion (using luciferase positive T-cells),
and cytokine production were examined. It was found that
murine recipients that lacked production of IL-12p40 by
host hematopoietic cells had lower survival, a lower level
of donor hematopoietic engraftment, a reduced percentage
TH1 cytokine producing donor T cells, and an increased
percentage of regulatory T cells in the spleen. This is the
first report that host-derived IL-12 plays a significant role
in engraftment and has implications for the use of IL-12
in transplant settings where graft failure is of concern.
Results
Host-hematopoietic-derived IL-12 enhances survival
after BMT
In order to examine the role of host-immune cell de-
rived IL-12, radiation chimeras were established in order
to create mice that lacked IL-12 in the hematopoieticcompartment only. One day prior to transplant, con-
genic B6 mice were lethally irradiated with 11 Gy total
body irradiation (TBI) and transplanted i.v. with 5 × 106
BM cells from B6 or IL-12p40 KO mice. A minimum of
50 days after transplant, donor chimerism of total nucle-
ated cells in the blood of both B6 and IL-12 KO radiation
chimeras was confirmed by flow cytometric analysis using
congenic markers (CD45.1, CD45.2, CD90.1, CD90.2)
(Figure 1A,B, representative data). Chimerism was found
to be greater than 95% in all radiation chimeras.
Radiation chimeras underwent a secondary transplant
following irradiation with 9 Gy TBI one day prior to
transplant. In B6 radiation chimeras, radioresistant host-
hematopoietic cells would be capable of producing IL-12
following irradiation and transplant, along with donor
hematopoietic cells. In IL-12 KO radiation chimeras only
the donor-derived hematopoietic cells would produce
IL-12, as residual host hematopoietic cells were of IL-12
KO origin.
One day after the second irradiation course, chimeras
were transplanted i.v. with 5 × 106 TCD BM cells from
FVB donors along with 3 × 105 luciferase positive (luc+)
FVB T-cells. Control transplant mice (syngeneic) were
FVB mice transplanted i.v. with 5 × 106 TCD BM cells
from FVB donors along with 3 × 105 luc + FVB T-cells.
Survival of mice was monitored daily. Weight loss and
clinical GvHD scores were monitored twice weekly
after transplant, as described by Cooke et al. [13]. IL-12
KO → WT mice had a median survival of 65 days post-
transplant (41% survival at day 105 post-transplant), which
was lower compared with WT → WT mice (median
survival day undefined, 75% survival at day 105 post-
transplant), though not significant (p = 0.24) (Figure 1C).
All syngeneic-transplanted mice survived to day 105.
Percent weight loss from initial starting weight and
GvHD scores were similar between WT→WTand IL-12
KO → WT radiation chimeras (Figure 1D,E,F). Control
transplanted mice did not experience weight loss after
transplant (Figure 1D).
Host-hematopoietic-derived IL-12 enhances donor T-cell
engraftment after BMT
Next we determined the effect of host hematopoietic
derived IL-12 on the engraftment of leukocytes, red
blood cells, and platelets. On day 30 post-transplant, we
measured the red blood cell (RBC) count, white blood
cell (WBC) count, platelet number, and hemoglobin
levels in the blood of recipient mice. Recipient mice in
which host immune cells were capable of producing
IL-12 had significantly higher erythroid engraftment as
seen by significantly higher RBC counts and hemoglobin
levels (Figure 2A,B respectively). WBC counts in the
blood of recipients previously engrafted with WT BM
were slightly higher, though not significant (Figure 2C).
Figure 1 Host-derived IL-12 enhances survival following BMT Radiation chimeras were established by lethally irradiating (11 Gy) B6
Pepboy (C57BL6/J congenic, CD45.1) mice followed by transplant with 5 × 106 BM Cells from either B6 (or BA – B6 congenic) or IL-12-p40
KO (B6 background) mice. Chimerism was confirmed a minimum of 50 days post-transplant by flow-cytometric analysis of congenic markers on
total nucleated cells (CD45.1, CD45.2) for both B6 (A) and IL-12p40 KO (B) chimeras. Flow plots are data from one representative mouse per group.
Chimeric mice were then conditioned with 9 Gy irradiation and transplanted with 5 × 106 FVB TCD BM cells along with 3 × 105 MACS-purified
luc + FVB T-cells. A syngeneic transplant was also performed using non-radiation chimera FVB mice as recipients. Survival (C), percent weight
loss from initial starting weight (D), and combined GvHD scores (E) were monitored after transplant. Data shown is combined from 3 independent
experiments of 4–5 mice per group (WT and IL-12p40 KO) or 3 mice per group (syngeneic).
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groups (Figure 2D). We also measured the percentage of
T cells of donor (FVB) origin as a percentage of totalT cells. Radiation chimeras previously engrafted with
WT BM had a higher percentage of donor T cells















































































































































































Figure 2 Host-derived IL-12 enhances erythroid and T-cell engraftment 30 days post-transplant. Radiation chimeras (B6 or BA and IL-12p40 KO)
were conditioned with 9 Gy irradiation and transplanted with 5 × 106 FVB TCD BM cells along with 3 × 105 MACS-purified luc + FVB T-cells. A syn-
geneic transplant was also performed using non-radiation chimera FVB mice as recipients. The levels of red blood cells (RBC) (A), hemoglobin (B), white
blood cells (WBC) (C), and platelets (D) were measured in the blood 30 days post-transplant. The percentage of cells of donor–origin (FVB) in the T-cell
compartment on day 30 post-transplant was determined by flow-cytometric analysis of congenic markers (CD45.1, CD45.2, CD90.1, CD90.2)
after gating on CD3+ cells (E). The percentage of mice in each group (WT or IL-12p40 KO) that exhibited greater than 50% FVB T-cell chimerism are
shown in (F). **, p < 0.01 comparing RBC of WT vs. IL-12p40 KO at day 30; *, p < 0.05 comparing Hemoglobin of WT vs. IL-12p40 KO at day 30.
Data shown is combined from 2 independent experiments of 4 mice per group (WT and IL-12p40 KO) or 3 mice per group (syngeneic).
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Standard deviation in Figure 2E is very high in both
groups, as most mice had engrafted primarily with FVB
(80% or higher donor T cells of FVB origin), or had failed
to engraft (lower than 40% donor T cells of FVB origin).
On day 30 post-transplant, 40% of WT → WT chimeras
had greater than 50% donor T cell engraftment, while only
10% of IL-12 KO → WT chimeras had greater than 50%donor T cell engraftment (Figure 2F). Mice that had failed
to engraft died. Among surviving mice on day 60 post-
transplant, 50% of WT → WT chimeras had greater than
50% donor T cell engraftment, compared with 40% of
IL-12 KO→WTchimeras (Figure 2F).
Since the radiation chimeras were transplanted with
FVB TCD BM and luciferase-positive FVB T-cells, donor
T-cell engraftment could be tracked using in vivo
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transplant. Mice were imaged every week beginning at
7 days post-transplant and continuing until 42 days
post-transplant. Representative imaging data from one
experiment is shown in Figure 3A. A greater percentage
of the WT → WT radiation chimeras had donor T cell
bioluminescent signals, and the signals were of greater
intensity, than that of IL-12 KO → WT radiation chi-
meras (Figure 3A). At day 42, only one IL-12 KO → WT
radiation chimera had a strong bioluminescent signal, and
the signal from donor T cells in 2/4 IL-12 KO→WTchi-
meras was not detectable. The strength of the signal from
each mouse in photons/second was quantified. WT →
WT chimeras had a higher average signal overall com-
pared with IL-12 KO → WT chimeras (Figure 3B). The
signal from WT → WT radiation chimeras was signifi-
cantly higher on D14 post transplant (p < 0.05), as well
as slightly higher on days 28 and 35 post-transplant (p =
0.092 and p = 0.098, respectively) (Figure 3B). T cells in
WT → WT mice had a bioluminescent signal strength
similar to or even higher than that of FVB mice receiving
a syngeneic transplant.
The absence of host-hematopoietic-derived IL-12 drives
donor CD4+ T-cells towards a tolerogenic phenotype
While survival and donor-T cell engraftment was higher
among WT radiation chimeras compared with IL-12 KO
radiation chimeras, we next aimed to determine whether
the phenotype of engrafted T cells was different between
groups. On day 10 post-transplant, percentages of T cells
expressing FoxP3, producing Tumor necrosis factor-α
(TNF-α) or interleukin-10 (IL-10), and expressing in-
duced costimulator (ICOS) or Programmed Death-1
(PD-1) were determined. IL-12 KO → WT chimeras had
a higher percentage of donor CD4 T cells expressing the
regulatory T cell marker FoxP3, as determined by intracel-
lular staining for FoxP3 (p < 0.05, Figure 4C). Representa-
tive flow plots for WT → WT and IL-12 KO → WT
radiation chimeras are shown in Figure 4A,B, respectively.
The ability of host hematopoietic cells to secrete IL-12p40
also had an impact on the percentage of donor CD4
T cells that produce IL-10 and TNF-α. A greater percent-
age of donor CD4+ T cells from WT chimeras produced
TNF-α compared with IL-12 KO chimeras (p < 0.01,
Figure 4D), while a slightly higher percentage of CD4+ T
cells from IL-12 KO chimeras produced IL-10 compared
with WTchimeras (p = ns, Figure 4E).
Signaling through ICOS has been shown to contribute
to BM graft rejection and GvHD [14]. We measured
ICOS expression in WT and IL-12 KO chimeras on
donor CD4 and CD8 T cells 10 days post-transplant.
IL-12 KO chimeras (gray dashed line) had higher expres-
sion of ICOS on CD4+, but not CD8+ T cells compared
with WT chimeras (black solid line) (representativehistograms, Figure 5A – CD4, 5B – CD8). Isotype con-
trol staining is indicated by a gray dotted line. The per-
centage of CD4+ T cells expressing ICOS was higher in
IL-12 KO chimeras (p < 0.01, Figure 5C), as well as the
median fluorescence intensity of the signal (p < 0.05,
Figure 5D), compared with WT chimeras.
The PD-1/Programmed Death Ligand 1 (PDL1) pathway
is critical for inducing peripheral deletional tolerance of
anti-donor CD8 T cells in BMT [15]. We analyzed the ex-
pression of PD-1 on CD4+ and CD8+ T-cells on day 10
post-transplant. Surprisingly, the level of PD-1 on the
surface of CD8+ T cells was similar between WT (solid
black line) and IL-12 KO chimeras (gray dashed line)
(Isotype control, gray dotted line) (Figure 5F). CD4+ T cells
in IL-12 KO → WT chimeras, however, had higher PD-1
expression (Figure 5E). The percentage of CD4+ T cells
expressing PD-1 was significantly higher in IL-12 KO →
WT chimeras (p < 0.05, Figure 5G), and the MFI was
slightly higher (Figure 5H), compared with WT → WT
chimeras. The percentages of CD8 T cells expressing
PD-1 and the MFI of the PD-1 signal were not different
comparing donor cells in WT→WT vs. IL-12 KO→WT
chimeras (Figure 5G,H).
Discussion
The role of host-derived IL-12 in engraftment has not
been examined previously. IL-12 promotes the main-
tenance of T-helper-type 1 (TH1) cells that are neces-
sary for elimination of residual host hematopoietic cells
in the process of engraftment. While increased TH1
polarization might be thought to increase GvHD, adminis-
tration of exogenous IL-12 has also previously been shown
to prevent GvHD while preserving GvL effects [8,16-18].
Proper engraftment is a paramount concern in clinical set-
tings such as when the donor is HLA-haploidentical to
the recipient, in cord blood transplants, and in patients
where non-myeloablative conditioning is used. Engraft-
ment is also a challenge in treatment of sickle cell anemia
with HSCT, due to prior host immunity resulting from
numerous blood transfusions in the patient’s history.
While IL-12 has been examined as a therapeutic agent
in reducing the severity of GvHD, we propose that these
findings could be translatable to promoting engraftment
in settings where graft failure is of concern.
In order to achieve stable engraftment in the presence
of cytotoxic host cells not eliminated by irradiation, it is
thought that host DCs directly activate donor T cells,
which then eliminate the remaining cytotoxic host cells.
Wang et al. showed that host DC can activate donor
CD4+ T cells, which in turn activate donor APC [14].
These donor APCs are then capable of cross presenting
minor histocompatibility antigens (miHA) in an MHC-
matched, miHA-mismatched, model to donor CD8+ Tcells
[14]. Production of IL-12 by DCs promotes maintenance of
Figure 3 Donor T cell engraftment is increased and occurs more rapidly in mice producing host immune-derived IL-12. Radiation
chimeras (B6 or BA and IL-12p40 KO) were conditioned with 9 Gy irradiation and transplanted with 5 × 106 FVB TCD BM cells along with 3 × 105
MACS-purified luc + FVB T-cells. A syngeneic transplant was also performed using non-radiation chimera FVB mice as recipients. (A) In-vivo
bioluminescent images of mice were taken weekly beginning 7 days post transplant and ending 42 days post transplant. The color bar represents
the scale used for the pseudocolor image. Images are representative from one of two independent experiments of 4–5 mice per group (3 mice
per group, syngeneic). (B) Total signal in the region of interest (ROI) (photons/sec) was determined for the whole-body on days 7, 13, 21, 28, 35,
and 42 post-transplant. ROI data has been log transformed, however statistical analyses were completed on raw data. Data are combined from two
independent experiments of 4–5 mice per group (3 mice per group, syngeneic); *, p < 0.05 comparing WT vs. IL-12p40 KO on day 14 post-transplant;
p = 0.092 and p = 0.098 comparing WT vs. IL-12p40 KO on days 28 and 35 post transplant, respectively.


































































































Figure 4 Host immune-derived IL-12 drives donor-T cells towards a Th1 phenotype. Radiation chimeras (B6 or BA and IL-12p40 KO) were
conditioned with 9 Gy irradiation and transplanted with 5 × 106 BA.B10 TCD BM cells and 3 × 105 MACS-purified B10.BR T-cells. Recipient splenocytes
were prepared 10 days post transplant and analyzed via flow-cytometry for the percentages of regulatory T cells as well as TNF-α and IL-10
producing donor T-cells. Donor-T cells were gated on using congenic markers (CD45.1, CD45.2, CD90.1) and CD3. Regulatory T cells were defined as T cells
expressing both CD4 and FoxP3. Representative flow plots for B6 (A) and IL-12p40 KO (B) radiation chimeras are shown. Percentages of FoxP3+ T cells in
the CD4 T cell compartment are shown in (C); *, p< 0.05 comparing WT vs. IL-12p40 KO. Data shown are from two independent experiments of 4–5 mice
per group. Percentages TNF-α and IL-10 producing CD4+ donor-T cells are shown in (D) and (E), respectively. IL-10 data are representative
from one of two independent experiments with 4–5 mice per group using pre-transplant irradiation of 9 Gy or 10 Gy (9 Gy is shown). TNF-α
data is combined from two independent experiments with 4–5 mice per group. **, p < 0.01 comparing WT vs. IL-12p40 KO.
Darlak et al. Journal of Hematology & Oncology 2014, 7:16 Page 7 of 12
http://www.jhoonline.org/content/7/1/16T cells in a TH1 phenotype after commitment to a TH1
lineage by T-bet and subsequent upregulation of the
IL-12β2 subunit of the IL-12 receptor on T cells [19,20].
Since IL-12 producing APCs are somewhat resistant to
radiation, we hypothesized that the production of IL-12
by residual host APCs would aid in the process of
engraftment by promoting TH1 immunity while not in-
creasing GvHD severity. Radiation chimeras were estab-
lished where all cells (host and donor) were capable of
producing IL-12 (WT → WT chimeras), as well as chi-
meras in which only the host hematopoietic cells were
incapable of IL-12 production (IL-12 KO → WT chi-
meras). A dose of 9 Gy was chosen for the second BMT
using radiation chimeras as recipients, as this is gener-
ally the highest tolerated dose for a second transplant.
Our results show that mice whose host hematopoietic
cells were capable of IL-12 production had increased
survival without higher levels of GvHD or increasedweight loss. Donor T cell engraftment in mice whose
residual host-hematopoietic cells lacked the ability to
produce IL-12 was reduced compared with WT → WT
mice, as seen by both flow cytometric analysis of chime-
rism, as well as in in vivo bioluminescent images of mice
engrafted with luc + donor T cells (Figure 2E,F, Figure 3).
WT → WT chimeras had a higher percentage of donor
CD4+ T cells producing TNF-α and a lower percentage of
CD4+ T cells producing IL-10 on day 10 following trans-
plant compared IL-12 KO→WT chimeras (Figure 4D,E).
This suggests that host derived IL-12 is promoting the
maintenance of donor T cells of a TH1 phenotype. These
host cells can prime donor CD8+ T cells to eliminate
cytotoxic host effectors that prevent engraftment.
WT → WT chimeras also had a lower percentage of
donor CD4+ T cells expressing the T-reg associated tran-
scription factor FoxP3+ compared with IL-12 KO → WT






























































































































Figure 5 (See legend on next page.)
Darlak et al. Journal of Hematology & Oncology 2014, 7:16 Page 8 of 12
http://www.jhoonline.org/content/7/1/16
(See figure on previous page.)
Figure 5 Host immune-derived IL-12 limits ICOS and PD1 expression by CD4+ donor T cells. Radiation chimeras (B6 or BA and IL-12p40 KO)
were conditioned with 9 Gy irradiation and transplanted with 5 × 106 BA.B10 TCD BM cells and 3 × 105 MACS-purified B10.BR T-cells. Recipient
splenocytes were harvested 10 days post transplant and analyzed via flow-cytometry. Donor T cells were gated on using congenic markers
(CD45.1, CD45.2, CD90.1) as well as CD3, and were then further differentiated using CD4 and CD8. Representative histograms are shown for
ICOS expression in CD4+ (A) and CD8+ (B) donor T-cells and PD1 expression in CD4+ (E) and CD8 + (F) donor T-cells (Isotype – fine dotted
line, WT – black solid line, IL-12p40 KO – gray dashed line). ICOS and PD-1 expression by CD4+ and CD8+ donor T cells was analyzed; Percentages of
donor T-cells expression ICOS (C) and PD1 (G) are shown as well as the median fluorescence intensity (MFI) of the signal for ICOS (D) and PD1 (H). **,
p < 0.01 comparing percentages of ICOS + CD4+ donor T-cells in WT vs. IL-12p40 KO; *, p < 0.05 comparing MFI of ICOS signal in CD4+ donor T-cells
in WT vs. IL-12p40 KO; *, p < 0.05 comparing percentages of PD1+ CD4+ donor T-cells in WT vs. IL-12p40 KO. Data shown for ICOS are representative
from one of two independent experiments with 4 mice per group using pre-transplant irradiation of 9 Gy or 10 Gy (9 Gy is shown). Data shown for
PD1 are combined from two independent experiments of 4 mice per group.
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unable to prime donor CD8+ T cells to eliminate cytotoxic
host cells. We also found that ICOS was present in higher
levels on CD4+ and CD8+ T cells in mice whose host-
hematopoietic cells were incapable of producing IL-12.
ICOS is a CD28 superfamily member whose expres-
sion is induced on CD4+ and CD8+ T cells following T
cell activation [21]. ICOS on T cells binds ICOS ligand
(ICOSL), which is upregulated on APCs activated by
TNF-α or TLR triggering by LPS [22,23]. ICOS binding
with ICOSL can stimulate IL-10 production by T cells
[21]. Taylor and Blazar found that ICOS blockade (via
either ICOS KO mice or ICOS monoclonal antibodies)
led to higher engraftment rates in mice receiving TCD
BM following non-myeloablative irradiation (5.5 Gy). Our
data coincides with these findings, as mice whose host-
hematopoietic cells did not produce IL-12 had lower
engraftment, and higher levels of ICOS on CD4+ and
CD8+ T cells (Figure 5A-D).
We also found higher percentages of PD-1+ CD4+ Tcells
in mice lacking the capacity to produce IL-12 by host
immune cells (Figure 5G). PD-1 is also a member of the
CD28 superfamily and is expressed by activated T cells
[24-26]. PD-1 binds to PDL1, which is expressed on all
hematopoietic and many non-hematopoietic cells, and PD
Ligand 2 (PDL2), which is found on DCs and macrophages
[27-30]. PD-1 binding with ligands leads to negative regula-
tion of activated T cells. The PD-1/PDL1 pathway is known
to induce deletional tolerance of alloreactive CD8+ but not
CD4+ T cells in BMT [15]. While we did not see a differ-
ence in the PD-1 expression of CD8+ T cells, there were
differences among CD4+ T cells. We speculate that the
higher percentages of PD-1+ CD4+ T cells in IL-12 KO
chimeric recipients could lead to generation of DC with
enhanced immunosuppressive properties [31,32].
It is important to note that the IL-12 KO mice used
in this study are IL-12p40 KO, resulting in recipient
mice deficient in both IL-12 and IL-23 in the host-
hematopoietic compartment. IL-23 is produced by acti-
vated DCs and macrophages upon pathogen recognition
receptor activation and can stimulate the proliferation of
human and mouse activated and memory T cells, butnot naïve T cells in vitro as well as induce IFN-γ produc-
tion by T cells [33]. IL-23 is also distinct from IL-12 in
that it promotes the maintenance of TH17 cells [34].
IL-23 is also produced by APCs following BMT, subse-
quently inducing IL-22 expression, which has been
shown to limit intestinal and liver GvHD pathology [35].
Interpretation of results must account for the potential
role of IL-23 in this system, along with the consideration
that while the host is lacking both IL-12 and IL-23,
donor hematopoietic cells are capable of producing
both cytokines. The absence of IL-12 and IL-23 in the
host hematopoietic compartment may lead to recipro-
cal changes in other cytokine and signaling pathways
[36,37]. Notably, we have previously shown that the
percentages of donor T-cells producing IL-17 were
increased in spleens from recipients transplanted with
IL-12p40 KO BM, compared with WT BM, 10 days
post-transplant [7].
Conclusions
Our results demonstrate that IL-12 production by re-
sidual host cells following irradiation and transplant is a
critical factor contributing to successful engraftment.
Mice whose host hemato-lymphoid cells lacked the cap-
acity to produce IL-12 had reduced donor T cell engraft-
ment, lower levels of erythroid engraftment, reduced
TNF-α production by donor T cells, higher percentages
of FoxP3+ CD4+ T cells, and higher expression of ICOS
and PD-1 on CD4+ T cells after transplantation. Ad-
ministration of exogenous IL-12 has been examined by
many groups as an anti-tumor therapy, as well as a
therapy for alleviating GvHD, and these results support




FVB/NJ (FVB, H-2Kq, CD45.1, CD90.1), C57BL6/J (B6,
H-2Kb, CD45.2, CD90.2), B10.BR (H-2Kk, CD45.2, CD90.2,
congenic B6 Pepboy (B6.SJL-PtprcaPep3b/BoyJ, H-2Kb,
CD45.1, CD90.2), and IL-12p40 KO (B6.129S1-Il12btm1Jm/J,
H-2Kb, CD45.2, CD90.2) mice were purchased from The
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expressing CD90.1 and CD45.2 on a B6 (H-2Kb) back-
ground (BA), and CD90.1, CD45.2 on a B10.BR (H-2Kk)
background (BA.B10) were backcrossed 10 generations
to the parental strain and bred at Emory University
Animal Care Facility (Atlanta, GA, USA). The luc +
transgenic mice (FVB-L2G85) on the FVB background
were a gift from Dr. Robert Negrin (Stanford University)
[38]. All transplant recipients were monitored daily for
survival. According to the Institutional Animal Care and
Use Committee (IACUC) protocol, moribund mice, mice
with greater than 25% weight loss, and mice surviving
until the end of the experiment, were euthanized and con-
sidered to have died on the day following euthanasia for
analysis of post transplant survival. Mice were scored for
clinical signs of GvHD by weight loss, posture, activity, fur
texture, and skin integrity twice weekly for the first 30 days
post transplant, and once weekly thereafter, using a GvHD
scoring system described by Cooke et al. [13]. Procedures
conformed to the National Institutes of Health (NIH,
Bethesda, MD) animal care guidelines and were approved
by the Emory University IACUC.
Cell preparation
Donor mice were killed in a humane manner and femurs,
tibias, and spleens were removed ascetically. BM cells and
splenocytes were harvested with sterile phosphate buff-
ered saline (PBS). T cells were purified by incubating sple-
nocytes with a cocktail of biotinylated anti-CD11b, anti-
B220, anti-DX5, and anti-TER119 antibodies, followed by
anti-biotin microbeads, and negative magnetic activated
cell sorting (MACS) selection using an LS magnetic
column (MACS, Miltenyi Biotec). CD3+ T cells were
depleted from BM cells by incubation of BM with bio-
tinylated CD3 antibodies, followed by anti-biotin micro-
beads, and negative MACS selection using an LS
magnetic column (MACS, Miltenyi Biotec).
Radiation chimeras
On day-1 prior to transplantation, recipient congenic B6
Pepboy mice (CD45.1) received a total of 11 Gy irradiation,
divided into two doses of 5.5 Gy given 3 hours apart [39].
On day 0, mice were injected i.v. with 5 million BM cells
from WT B6 donors (CD45.2) or IL-12p40 KO donors
(CD45.2). Chimerism was confirmed a minimum of 50 days
post-transplant using flow cytometric analysis of blood
stained with anti-CD3-PE-Cy7, anti-CD19-APC-Cy7, anti-
CD45.1-PE, anti-CD45.2-FITC, anti-CD90.1-PerCP, and
anti-CD90.2-APC (BD Biosciences, San Diego, CA).
Secondary transplant
On day-1 prior to transplantation, recipient chimeric
mice (B6/BA or IL-12p40 KO) (CD45.2, CD90.2) re-
ceived a total of 9 Gy irradiation, divided into two doses of4.5 Gy given 3 hours apart [39]. On day 0, mice were
injected i.v. with 5 × 106 T-cell depleted (TCD) BM cells
from FVB donors (H-2Kq CD45.1, CD90.1) along with 3 ×
105 MACS-purified T-cells from luc + FVB donors. FVB
mice that had not undergone an initial radiation chimera
transplant were used as syngeneic control mice, and re-
ceived a transplant identical to the radiation-chimera
mice. Secondary transplants corresponding to experi-
ments shown in Figures 4 and 5 were done using BA.B10
(H2Kk, CD45.2, CD90.1) bone marrow donors and B10.
BR (H2Kk, CD45.2, CD90.2) T-cell donors. All transplant
recipients were monitored for survival and clinical signs
of GvHD daily. Mice were scored for clinical signs of
GvHD by weight loss, posture, activity, fur texture, and
skin integrity twice weekly for the 30 days, and then
weekly as described by Cooke et al. [13]. According to
IACUC protocol, moribund mice, mice with greater than
25% weight loss, and mice surviving until the end of the
experiment, were euthanized and considered to have died
on the day following euthanasia for analysis of post-
transplantation survival.
Flow cytometry
For chimerism analysis, peripheral blood was collected
on days 30, 60 and 100 (+/− 5 days) in tubes containing
20 μl heparin from the tail vein of transplant recipients.
For flow cytometric analysis, red blood cells were lysed
via incubation in an ammonium chloride lysis buffer.
Host- and donor-derived leukocytes and T-cells were
measured by flow cytometry using monoclonal anti-
bodies for specific leukocyte markers expressed on B6,
congenic B6 Pepboy, IL-12p40 KO, FVB, B10.BR, and
BA.B10 strains (anti-mouse CD3-APC, CD45.1-APC-Cy7,
CD45.2-FITC, H2kb-PE; BD Biosciences, San Diego, CA).
Spleen samples were obtained on day 10 post transplant
and intracellular cytokine expression of IFN-γ, TNF-α,
IL-10, and IL-17 by donor CD4+ and CD8+ T-cells was
analyzed by using a Cytofix/Cytoperm Kit (BD Biosciences,
San Diego, CA). Presence of donor regulatory T cells in
the spleen on day 10 post transplant was analyzed by
surface staining using anti-mouse CD3-PE-Cy7, CD90.2-
APC, H-2Kk-FITC, CD4-Alexa-700 and CD25-APC-Cy7,
followed by intracellular staining of FoxP3-PE (BD
Biosciences, San Diego, CA). All samples were analyzed
on a FACS Canto (Beckton Dickinson, San Jose, CA) and
list mode files were analyzed using FlowJo software (Tree
Star, Inc 2007, Ashland, OR). Cells staining positive for
cytokines and FoxP3 were determined as those exhibiting
a fluorescence signal greater than that of a corresponding
isotype-control antibody (BD-Biosciences).
In vivo bioluminescent imaging
In vivo bioluminescent imaging (BLI) was performed
using a cooled charge-coupled device (CCD) camera
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CA, USA). Mice received a subcutaneous injection of
D-luciferin (0.15 mg/g body weight; Firefly luciferin po-
tassium salt, Xenogen, Alameda, CA, USA). Ten minutes
later, mice were placed in the chamber of the CCD camera
system under rodent cocktail (ketamine 20 mg/ml and
xylazine 2.5 mg/ml, 0.1 ml/25 g body weight) anesthesia.
Photographic and luminescent images in the ventral pro-
jection were obtained using a 3-minute exposure time. Up
to five mice were imaged simultaneously. On each in vivo
BLI image, a region of interest (ROI) encompassing the
entire mouse was created, and the whole-body signal in
the ROI (photons/sec) was quantified using Living Image
software (Version 3.2, Xenogen, Alameda, CA, USA). The
whole-body bioluminescent signal was used as a marker
of the donor T-cell engraftment.
Statistical analyses
Analyses of data were performed using Prism version 5 for
Mac (GraphPad Software, San Diego, CA, www.graphpad.
com). Data are presented as mean ± standard deviation
(SD) of all evaluable samples. Survival differences between
groups were calculated with the Kaplan-Meier log-rank
test in a pair-wise fashion. Differences in the numbers of
cells present in blood, bioluminescence ROI values, per-
centages of FoxP3+, cytokine-producing, and PD-1 or
ICOS expressing cells were performed using a two-tailed
unpaired Student’s t-test or a one-way analysis of variance
(ANOVA) followed by a Bonferroni post-test to adjust for
multiple comparisons. P-values of less than 0.05 were
considered significant.
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